All In Biotech

Drug Trial Radar · NCT04094610

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Mar 12, 2020

Primary completion

Sep 30, 2026

Study completion Sep 30, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.

Conditions

  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lymphoma
  • Primary CNS Tumors

Interventions

  • Oral repotrectinib (TPX-0005)Drug

    Oral repotrectinib (TPX-0005)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs) (Phase 1)Time frame: Within 28 days of the first repotrectinib dose
  2. Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Within 28 days of the last patient dosed in escalation
  3. Overall Response Rate (ORR) (Phase 2)Time frame: Two to three years after first dose of repotrectinib

Locations

68 sites in 11 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • University of California at Los Angeles

    Los Angeles, California · Recruiting

  • Children's Hospital Colorado - Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Local Institution - 2105

    Orlando, Florida · Completed

  • Local Institution - 2120

    Orlando, Florida · Completed

  • Children's Healthcare of Atlanta - Egleston Hospital

    Atlanta, Georgia · Recruiting

  • Maine Medical Center

    Scarborough, Maine · Recruiting

  • Dana Farber Cancer Institute.

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri · Recruiting

  • Local Institution - 2110

    New Brunswick, New Jersey · Completed

  • Local Institution - 2102

    New York, New York · Completed

  • Levine Children's Hospital- Pediatric Neuro-Oncology

    Charlotte, North Carolina · Recruiting

  • Local Institution - 2112

    Cleveland, Ohio · Completed

  • Local Institution - 2114

    Hershey, Pennsylvania · Completed

  • Children's Hospital of Philadelphia-Center for Childhood Cancer Research

    Philadelphia, Pennsylvania · Recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

  • The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center

    Dallas, Texas · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Local Institution - 2104

    Houston, Texas · Completed

  • Children's Hospital of Richmond at VCU

    Richmond, Virginia · Withdrawn

  • Local Institution - 6104

    Randwick, New South Wales, Australia · Recruiting

  • Local Institution - 6103

    Westmead, New South Wales, Australia · Completed

  • Children's Health Queensland Hospital and Health Service

    South Brisbane, Queensland, Australia · Recruiting

  • Perth Childrens Hospital

    Nedlands, Western Australia, Australia · Recruiting

  • University Of Calgary

    Calgary, Alberta, Canada · Recruiting

  • Stollery Children'S Hospital

    Edmonton, Alberta, Canada · Recruiting

  • Children'S Hospital Of Eastern Ontario

    Ottawa, Ontario, Canada · Recruiting

  • St Justine Hospital

    Montreal, Quebec, Canada · Recruiting

  • Rigshospitalet - Glostrup

    Copenhagen, Denmark · Recruiting

  • Centre Hospitalier Universitaire D'Angers

    Angers, France · Recruiting

  • Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Pellegrin

    Bordeaux, France · Recruiting

  • Institut d Hematologie et d Oncologie Pediatriques

    Lyon, France · Recruiting

  • Hôpitaux Universitaires de Marseille Timone

    Marseille, France · Recruiting

  • Local Institution - 6110

    Marseille, France · Not yet recruiting

  • Local Institution - 6112

    Nantes, France · Not yet recruiting

  • Local Institution - 6109

    Paris, France · Not yet recruiting

  • Institut Gustave-Roussy

    Villejuif, France · Recruiting

  • Local Institution - 6108

    Villejuif, France · Not yet recruiting

  • Local Institution - 6111

    Lyon, Rhone, France · Not yet recruiting

  • Fondazione IRCCS - Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.